key: cord-0950567-riqqskad
authors: Williams, V.; Dash, N.; Suthar, R.; Mohandoss, V.; Jaiswal, N.; Kavitha, T.; Nallasamy, K.; Angurana, S. K.
title: Clinico-laboratory profile, intensive care needs, treatment details, and outcome of Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): A systematic review and Meta-analysis.
date: 2020-10-25
journal: nan
DOI: 10.1101/2020.10.21.20217034
sha: a1f8ef95b9c06f0aa5f22534bc71b8802983bcf9
doc_id: 950567
cord_uid: riqqskad

Objectives: To synthesize the current data on clinico-laboratory features, intensive care needs, treatment, and outcome of Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) or multisystem inflammatory syndrome in children (MIS-C). Data Sources: Articles published in PubMed, Web of Science, Scopus, Google Scholar, and WHO COVID-19 research database, CDC database, and Cochrane COVID-19 study register between 1st December 2019 to 10th July 2020. Study Selection: Observational studies involving patients [≤]21 years with PIMS-TS or MIS-C, that reported the clinico-laboratory features, intensive care needs, treatment, and outcome. Data Extraction: The search identified 422 citations and finally 18 studies with 833 participants were included and pooled estimate was calculated for parameters of interest utilising random effect model. Data Synthesis: The median age was 9 (8-11) years. Fever, gastrointestinal symptoms, rash, conjunctival injection, and respiratory symptoms were common clinical features. Majority had positive SARS-CoV-2 antibody test and only 1/3rd had RT-PCR positive. The commonest laboratory abnormalities were elevated CRP, D-dimer, procalcitonin, BNP, fibrinogen, ferritin, troponin, and IL-6; and lymphopenia, hypoalbuminemia, and thrombocytopenia. The cardiovascular complications included shock (65%), myocardial dysfunction (61%), myocarditis (65%), and coronary artery abnormalities (39%). Three-fourth children required admission in PICU for mechanical ventilation (25%) and vasoactive drugs (61%). The common treatment provided was IVIG (82%), steroids (54%), antiplatelet drugs (64%), and anticoagulation (51%). The mortality was low (n=13). Conclusion: Fever, gastrointestinal and mucocutaneous symptoms, cardiac dysfunction, shock, and hyperinflammation are common manifestations of PIMS-TS or MIS-C. The short-term outcome is good with supportive intensive care and immunomodulatory treatment.

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected almost all the countries, overwhelming the healthcare system, and causing significant mortality . [1] [2] [3] [4] [5] [6] The severe COVID-19 typically present in 2 nd week of illness coinciding with decrease in viral load and increase in inflammatory markers. The host tissue damage is thought to be mediated by dysregulated and aberrant innate and adaptive immune response. [7] [8] [9] [10] [11] Acute respiratory failure is the most common organ dysfunction in severe COVID-19 though other organ systems including cardiovascular system may be involved. [7] [8] [9] As compared to adults, children are less frequently affected with mild symptoms in majority. [1] [2] [3] In mid-April 2020, clinicians from the United Kingdom (UK) reported a cluster of eight previously healthy children who presented with hyperinflammatory shock syndrome which was reported to be temporally associated with COVID-19. [12] The Royal College of Kawasaki-like syndrome were published from the countries with high case load of COVID-19 like the UK, France, Italy, and the United States of America (USA) describing the demographic details, clinical features, investigations, treatment details, and outcome. The case fatality of COVID-19 in children with PIMS-TS or MIS-C is higher than those without PIMS-TS or MIS-C.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 25, 2020. ; https://doi.org/10.1101/2020. 10.21.20217034 doi: medRxiv preprint Methodology:

This systematic review was conducted as per the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. [34] The review was registered in PROSPERO (CRD42020198231).

Three investigators (KN, VW, and SKA) performed independent literature search in electronic databases including PubMed, Web of Science, Scopus, Google Scholar, and WHO COVID-19 research database, CDC database, and Cochrane COVID-19 study register of original articles published between 1 st December 2019 and 10 th July 2020 using predefined search strategy targeting children and adolescents ≤ 21 years with PIMS-TS or MIS-C. In addition, preprints from medRxiv and bioRxiv were also screened.

The combination of the following keywords was used as the search strategy for literature search:

• Age group (infants, children, adolescents) with an age restriction of 21 years. The references of included studies and review articles were retrieved and screened.

Articles published in the English language were included. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was followed. [35] . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 25, 2020. 6. Other studies that do not meet the inclusion criteria or lack enough data on patient characteristics.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 25, 2020. ; https://doi.org/10.1101/2020.10.21.20217034 doi: medRxiv preprint

We used a pre-designed standardized proforma for data extraction. The data entry was be done on Microsoft Excel. Three investigators (VW, KN, and SKA) extracted the data independently from the full text and supplementary contents of the eligible studies. The data collected included first author's name, journal name and the year of publication, country, study design, number of centres, number of cases, study population, age and sex distribution, Any disagreement at any point between three investigators was sorted out through discussion and consensus with other two investigators (RS and VM). The data so extracted was rechecked by independent researchers for its accuracy and completeness (ND, KTK, and NJ). To avoid duplicity of the data, efforts were made to screen full text of all included studies for author names, setting, location, date and duration of the study, number of participants, and baseline data.

The quality of included studies was assessed using the National Institute of Health Study Quality Assessment Tools for case series studies and observational cohort and crosssectional studies. The overall risk of bias to each included study was independently assessed by three investigators (VW, KN, and SKA). If any disagreement, other investigators (ND, RS, and VM) were involved to resolve the disagreement. The studies were rated as either having low-or high-risk of bias.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 25, 2020. ; https://doi.org/10.1101/2020.10.21.20217034 doi: medRxiv preprint

The outcome of this systematic review was to provide pooled estimate of demographic details, clinical features, laboratory investigations, intensive care needs, treatment details, and outcome (mortality) among children and adolescents (≤21 years) with PIMS-TS or MIS-C.

The initial data entry was done . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 0

The search identified 422 articles. The 233 duplicate articles and 69 irrelevant articles were removed. Out of 120 full text articles assessed, 102 articles were removed as per the exclusion criteria, and finally 18 articles were included in the final analysis ( Figure 1 ). On quality assessment, eight studies were judged to have had low-risk of bias. [13, 15-17, 21, 22, 27, 28] while 10 had high-risk of bias. [14, 18-20, 23-26, 29, 30] (Table 1 )

In 18 studies, 833 children were reported. All the studies were conducted between 1 st March and 23 rd May 2020 with median (IQR) length of the study duration being 39 (24-56) days. Seven studies were from the USA [13, 15, 18, 21, 22, 25, 27] and 11 were from Europe [14, 16, 17, 19, 20, 23, 24, 26, [28] [29] [30] with almost 50% cases from each region. The studies from Europe include 4 studies from UK [16, 17, 19, 28] , 5 from France [14, 23, 24, 26, 29] , 1 from France and Switzerland [20] , and 1 from Italy. [30] Nine studies were single centre [18, 19, 21, 23, 25, [27] [28] [29] [30] and 9 were multicentre studies. [13-17, 20, 22, 24, 26] The study design was retrospective in 14 studies, [15, [17] [18] [19] [20] [21] [22] [24] [25] [26] [27] [28] [29] [30] retrospective and prospective in 3, [13, 14, 16] and prospective in 1 study. [23] The criteria used to define the inflammatory syndrome in children in temporal relation to COVID-19 was CDC and/or New York State Department of Health (NYSDOH) criteria in 6 studies, [13, 15, 18, 21, 22, 27] RCPCH criteria in 5 studies, [14, 16, 17, 19, 28] and American Heart Association (AHA) KD criteria in 5 studies. [23, 25, 26, 29, 30] Two studies enrolled cases with fever, shock, acute myocarditis/left ventricular (LV) dysfunction, and evidence of inflammation. [20, 24] (Table 2) There was overlap of few cases in studies from UK, [16, 17, 19, 28] France, [26, 29] and USA. [22, 27] As the information to identify overlapping cases could not be derived, after discussion among 3 authors (VW, KN, and SKA), consensus was reached to include all these studies in the systematic review.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 1

All except one study (15) reported median (IQR) age and it was 9 (8-11) years. All studies reported gender and males were 57%. The median (IQR) duration of illness/fever was 5 (4-6) days as reported in 11 studies. [13, 16, 20-26, 28, 30] Race was reported in 12 studies [13, 15-18, 21-23, 25, 26, 28, 30] and common races noted were black (35%), white (27%), Asian (10%), and others (14%). All except 4 studies [14, 19, 28, 29] reported comorbidities (29%); common comorbidities noted were underlying respiratory, cardiac, immunocompromising, autoimmune diseases, and obesity (Table 3) .

Fever was the most common symptom reported in 96% children in all except one study. [14] Gastrointestinal symptoms (pain abdomen, nausea/vomiting, and diarrhea) were noted in 86% in all expect 2 studies. [14, 29] Other common clinical features noted were rash (58%), conjunctival injection (52%), respiratory symptoms (43%), oral mucosal changes (42%), peripheral extremity changes (39%), neurological symptoms (32%), cervical lymphadenopathy (24%), and musculoskeletal symptoms (17%) ( Table 3 ).

The results of SARS-CoV-2 antibody test and RT-PCR were reported by all studies and these were positive in 84% and 37% children, respectively (Table 3) .

The laboratory investigations are shown in Supplemental table 1. Radiological investigations were reported in 11 studies [13, 15, 18, 19, 22, 23, [25] [26] [27] [28] 30] and the findings are described in Supplemental table 2. Lymphopenia was noted in 85% and thrombocytopenia in 53% children. Among inflammatory markers, elevated CRP was noted in 98% children, elevated procalcitonin in 90%, elevated fibrinogen in 86%, elevated ferritin in 82%, and elevated IL-6 in 68% children. Elevation of D-dimer was noted in 92% children, hypoalbuminemia in 71%, and elevated ALT in 40%. Among cardiac markers, 89% children had elevated BNP (NT-BNP or Pro-BNP) and 78% had elevated troponin (Table 4) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 25, 2020. ; https://doi.org/10.1101/2020. 10.21.20217034 doi: medRxiv preprint Sixteen studies reported data on echocardiography which was done in 94% children. [13, [15] [16] [17] [18] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] The common echocardiographic abnormalities include LV dysfunction or ejection fraction <55% (61%), myocarditis (as defined by clinical and/or biochemical and/or echocardiographic diagnosis) (65%), any coronary artery abnormality (39%), pericardial effusion (35%), coronary artery dilatation or aneurysm (16%), and coronary artery diameter >2.5 z-score (8%) children. About 10% children had residual LV dysfunction at discharge as reported in eight studies. [20-22, 24-26, 28, 30] (Table 4 )

All studies reported intensive care admission and 76% children were managed in PICU where they received high flow nasal cannula oxygen (18%), non-invasive ventilation (22%), and invasive ventilation (25%). Shock was noted in 65% children and 61% required vasoactive/inotropic drugs. Acute kidney injury was noted in 35% children and 2% underwent RRT. The requirement of ECMO was reported in all except 3 studies [14, 26, 30] and it was used in 4% children (n=32) ( Table 5) .

All except two studies [14, 19] reported data on intravenous immunoglobulin (IVIG) and steroids use that were given to 82% and 54% children, respectively. The second dose of IVIG was used in 25% of children who did not show improvement after the first dose. [13, 20, 21, 23, 26, [28] [29] [30] The combination of steroid plus IVIG was used in 50% children. [13, 15, 23, 30] Other biological and immunomodulator agents used were IL-6 inhibitors (12.6%) and IL-1Ra inhibitor (8.6%). Sixteen children received infliximab, 1 rituximab, and 5 received convalescent plasma therapy. Anticoagulation (prophylactic or therapeutic) and antiplatelet agents (any dose) were used in 51% and in 64% children, respectively (Table 5) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

All studies reported the number of deaths. There were 13 deaths with pooled estimate% (95% CI) of 2 (1-3). The data on hospital discharge was given in all except one study. [14] Majority of children (95%) were discharged at the time of reporting and only 3.6%

were still hospitalized (n=77). The median (IQR) duration of hospital stay was 7.8 (5) (6) (7) (8) (9) (10) days (Table 5) .

We compared the studies from the USA and Europe region. Significant differences between two regions include differences in criteria used (USA: CDC and/or NYSDOH criteria; Europe: RCPCH and AHA KD criteria); higher proportion of children with comorbidity (36% vs. 19%, p=0.04), and greater frequency of treatment with IL-6 inhibitors (27% vs. 4%, p=0.02) and IL-1Ra inhibitors (13% vs. 5%, p=0.004) in studies from the USA;

and higher need of mechanical ventilation in studies from Europe (33% vs. 12%, p=0.03) (Supplemental table 3 ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 25, 2020. ; https://doi.org/10.1101/2020.10.21.20217034 doi: medRxiv preprint

In this systematic review, we summarized the epidemiological and clinical features, investigations, intensive care needs, treatment details, and outcome of children and adolescents (<21 years) with PIMS-TS or MIS-C. This illness is characterized by febrile hyperinflammatory state with gastrointestinal, mucocutaneous, dermatological, and cardiac manifestations. The peak incidence occurred about a month after the peak of COVID-19 epidemic (when COVID-19 activity was decreasing) and then the incidence decreased thereafter. [13] [14] [15] [16] 30] . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 25, 2020. ; https://doi.org/10.1101/2020.10.21.20217034 doi: medRxiv preprint

We noted that most children were older (median age 9 years), previously healthy, and presented 4-6 weeks after the peak of COVID-19. The proportion of children belonged to black race were higher (35%) similar to what was noted in adults with severe clinical presentations of COVID-19 for which a possible genetic predisposition needs to be explored. [36] The most common presenting symptoms were fever, GI symptoms, rash, conjunctival injection, respiratory symptoms, and oral mucosal changes. GI symptoms (86%) were strikingly prominent. [13, 15-22, 24-26, 28, 30] mimicking GI infection, acute abdomen, or inflammatory bowel disease. [18, 19, 37] The possible mechanisms for the GI symptoms could be bowel wall edema or ischemia due to vasculitis, cardiac dysfunction and/or shock, mesenteric inflammation, and mesenteric lymphadenitis. [19, 23, 37] The symptom complex of fever, GI symptoms, and rash in children with SARS-CoV-2 infection (symptomatic or asymptomatic) in recent past (2-4 weeks prior) should alert clinicians to early recognize this syndrome, prompt investigation for hyperinflammation and organ dysfunction, close monitoring (including hemodynamic monitoring, electrocardiography, and echocardiography), and aggressive supportive and specific therapy.

Majority of children had elevated inflammatory markers (CRP, procalcitonin, fibrinogen, ferritin, D-dimer, IL-6), lymphopenia, hypoalbuminemia, and thrombocytopenia.

These hyperinflammatory manifestations noted were similar to adults with COVID-19. [38, 39] Among cardiac manifestations, 65% children had evidence of myocarditis, 61% had evidence of LV dysfunction, 16% had coronary dilatation or aneurysm with 8% documented coronary artery diameter >2.5 z-score. About 10% children had residual LV dysfunction at discharge. In adults with COVID-19, myocardial dysfunction has been observed to be a prominent extrapulmonary manifestation that was associated with increased mortality. [40, 41] The common chest radiological abnormalities noted in children with COVID-19 are bronchial thickening, ground-glass opacities, or inflammatory lung lesions, suggestive of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 25, 2020. ; https://doi.org/10.1101/2020.10.21.20217034 doi: medRxiv preprint pneumonia. These lung findings were also noted in asymptomatic children and those with mild symptoms, suggesting that SARS-CoV-2 infection induces a primary inflammation of lung parenchyma and lower respiratory tract. [42, 43] The reporting of radiological features was not uniform in included studies.

Most children with acute SARS-CoV-2 infections are usually asymptomatic or having mild symptoms, [1] [2] [3] [4] while majority with PIMS-TS or MIS-C were noted to have severe disease requiring PICU admission (76%), vasoactive drugs (61%), and invasive mechanical ventilation (25%). The most common treatment strategies used were IVIG (82%) and steroids (54%). Small proportion of children also received IL-6 inhibitors, IL-1Ra inhibitor, infliximab, rituximab, and convalescent plasma therapy. Antiplatelets and anticoagulation were used in 64% and 51% children, respectively. The short-term morbidity was high in terms of higher requirement of intensive care interventions, but the mortality was low.

The presentation of PIMS-TS or MIS-C had some overlapping features with KD, TSS, HLH, or MAS. [15, 16] However, it differed from KD on following accounts: older age at presentation (older children and adolescents); higher proportion of children with GI and respiratory symptoms; predominance of severe cardiovascular system involvement in form of shock, LV dysfunction, or myocarditis; higher proportion of lymphopenia, thrombocytopenia, and elevated CRP and procalcitonin; and more children being cared in PICU and requiring vasoactive drugs and mechanical ventilation. [11-13, 15, 16, 20, 30] As per the available data, it seems that PIMS-TS or MIS-C is an uncommon manifestation of SARS-CoV-2 infection reported at greater frequency among specific age group, ethnicity (blacks), and region (scarcity of reports from Asia including China). These differences could be due to differences in exposure to SARS-CoV-2 infection, incomplete

reporting, non-severe disease, predominance of SARS-CoV-2 infection among black race, differences in nasal expression of angiotensin-converting enzyme 2 (ACE2) receptors for . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 25, 2020. ; https://doi.org/10.1101/2020.10.21.20217034 doi: medRxiv preprint SARS-CoV-2 cell entry; socioeconomic status, and comorbidities. The susceptibility to inflammatory disease and response to treatment may also be influenced by the gut microbiome, signalling pathways, genetic variations and other host factors; and early treatment with immunomodulators. [9, 13, 16, 44, 45] There is great variation among clinicians in the use of immunomodulatory treatments of PIMS-TS or MIS-C and IVIG and steroids were used most commonly. However, good quality evidence from well-designed clinical trials are required to establish treatment guidelines. In absence of definite evidence of specific treatment, the supportive intensive care and multidisciplinary approach (intensivist, infectious disease specialist, cardiologist, haematologist, immunologist/rheumatologist, and pharmacologist) remains crucial for clinical management.

This systematic review has several strengths. To the best of our knowledge, this is the first review that summarized the available literature on epidemiology, clinical features, investigations, intensive care needs, treatment, and outcome of children with PIMS-TS or MIS-C. The search strategy was rigorous to include all studies that reported children with hyperinflammatory syndrome associated with COVID-19 irrespective of the description (PIMS-TS, MIS-C, KD, cardiac involvement, acute heart failure, acute myocarditis, GI manifestations, or imaging findings). We also performed a sub-group analysis to compare studies from two continents (USA and Europe) which did not demonstrate significant differences in characteristics despite ethnic differences.

The systematic review also has several limitations. All the included studies were conducted over a short period of time. Most of the studies were retrospective and with small sample size. More than half of the studies had high-risk of bias. The criteria used were different across the region. There was a small overlap of few cases in few studies which we could not delineate. The long-term follow-up data was not available which is needed to . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 8 identify long-term health issues (especially those with myocardial dysfunction and coronary artery abnormalities). We do not have studies from other countries with high burden of COVID-19 (Brazil, India, Russia, South Africa, Mexico, Spain etc.) at the time this review was performed which could possibly contribute to publication bias.

The children with PIMS-TS or MIS-C were reported from the USA and Europe . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 25, 2020. ; https://doi.org/10.1101/2020.10.21.20217034 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 25, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 25, 2020. ; https://doi.org/10.1101/2020.10.21.20217034 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 25, 2020. ; https://doi.org/10.1101/2020.10.21.20217034 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 25, 2020. ; https://doi.org/10.1101/2020.10.21.20217034 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 25, 2020. ; https://doi.org/10.1101/2020.10.21.20217034 doi: medRxiv preprint

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review

SARS-CoV-2 Infection in Children

Clinical Features and Outcome of SARS-CoV-2 Infection in Children: A Systematic Review and Meta-analysis. Indian Pediatr

The clinical characteristics of pediatric inpatients with SARS-CoV-2 infection: A meta-analysis and systematic review

Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and metaanalysis

Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies

Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

COVID-19: immunopathology and its implications for therapy

Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children

Hyperinflammatory shock in children during COVID-19 pandemic

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study

Multisystem Inflammatory Syndrome in Children in New York State

Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort

Multisystem Inflammatory Syndrome in Children (MIS-C) Related to COVID-19: A New York City Experience

Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital

Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a timeseries analysis. Lancet Child Adolesc Health

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Serology confirms SARS-CoV-2 infection in PCR-negative children presenting with Paediatric Inflammatory Multi-System Syndrome

Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series

Acute myocardial injury: a novel clinical pattern in children with COVID-19. Lancet Child Adolesc Health

Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Is ethnicity linked to incidence or outcomes of covid-19?

Gastrointestinal features in children with COVID-19: an observation of varied presentation in eight children

Clinical Characteristics of Covid-19 in New York City

Dysregulation of Immune Response in Patients With Coronavirus

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Coronavirus 2019-nCoV: A brief perspective from the front line

Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus